QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
Log in
ARCA:MTNB

Matinas BioPharma Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume1.38 million shs
Market Capitalization$160.35 million
P/E RatioN/A
Dividend YieldN/A
Beta2.95
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was founded in 2013 and is based in Bedminster, New Jersey.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.00 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone908 443 1860
Employees21

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90,000.00
Book Value$0.18 per share

Profitability

Net Income$-17,370,000.00

Miscellaneous

Market Cap$160.35 million
Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive MTNB News and Ratings via Email

Sign-up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Matinas BioPharma (ARCA:MTNB) Frequently Asked Questions

What stocks does MarketBeat like better than Matinas BioPharma?

Wall Street analysts have given Matinas BioPharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Matinas BioPharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Matinas BioPharma's key competitors?

Who are Matinas BioPharma's key executives?

Matinas BioPharma's management team includes the following people:
  • Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 46, Pay $644.79k)
  • Mr. Keith A. Kucinski CPA, M.B.A., Chief Financial Officer (Age 50, Pay $249.05k)
  • Dr. Theresa Matkovits, Chief Devel. Officer (Age 53, Pay $380.62k)
  • Dr. James J. Ferguson, Chief Medical Officer (Age 67, Pay $490.85k)
  • Dr. Raphael J. Mannino, Chief Scientific Officer (Age 73)
  • Ian Cooney, Director of Investor Relations & Corp. Devel.
  • Mr. Frank Calamusa, Exec. Director and Head of Manufacturing & Supply Chain

What is Matinas BioPharma's stock symbol?

Matinas BioPharma trades on the ARCA under the ticker symbol "MTNB."

How do I buy shares of Matinas BioPharma?

Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Matinas BioPharma?

Matinas BioPharma has a market capitalization of $0.00 and generates $90,000.00 in revenue each year. The company earns $-17,370,000.00 in net income (profit) each year or ($0.13) on an earnings per share basis. Matinas BioPharma employs 21 workers across the globe.

What is Matinas BioPharma's official website?

The official website for Matinas BioPharma is www.matinasbiopharma.com.

How can I contact Matinas BioPharma?

Matinas BioPharma's mailing address is 1545 ROUTE 206 SOUTH SUITE 302, BEDMINSTER NJ, 07921. The company can be reached via phone at 908 443 1860 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.